ArticleCureus2026
A Case of Duodenal Metastasis From a Poorly Differentiated Lung Carcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the leading causes of cancer-related mortality worldwide and commonly metastasizes to the brain, bones, liver, and adrenal glands, whereas gastrointestinal (GI) involvement is uncommon and rarely diagnosed during a patient's lifetime. We report a rare case of poorly differentiated carcinoma of the lung with duodenal metastasis. The patient was a 73-year-old man who presented with abdominal pain and melena, prompting esophagogastroduodenoscopy (EGD), which revealed ulcerated duodenal lesions. Histopathologic examination of the duodenal biopsy demonstrated a poorly differentiated carcinoma morphologically similar to the known lung tumor. Immunohistochemical analysis showed positivity for pancytokeratin (AE1/AE3) and PD-L1, with negative staining for TTF-1, CK7, CDX2, CK5/6, p63, neuroendocrine markers, and lymphoid markers, supporting metastatic disease when considered alongside the patient's known primary lung malignancy and clinicopathologic findings. As the lesions were neither actively bleeding nor causing obstruction, no endoscopic or surgical intervention was required. Despite initiation of oncologic therapy, the patient's condition rapidly deteriorated, and he died during the same hospitalization. The interval from diagnosis of the primary lung tumor to identification of GI involvement was only two months, followed by a further survival of 28 days after identification of duodenal involvement. This report underscores the importance of maintaining a high index of suspicion for GI metastases in patients with lung cancer who develop GI symptoms, as timely recognition may facilitate appropriate diagnostic evaluation and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.